Congress urges HHS to update HIPAA mHealth guidance

The Department of Health and Human Services (HHS) is long overdue to update its HIPAA guidance to better regulate the rapidly evolving mobile health industry market, according to two House representatives.

Following up on a letter sent to him from ACT|The App Association, Rep. Tom Marino (R-Penn.), along with Peter DeFazio (D-Ore.), sent a letter to HHS Secretary Sylvia Mathews Burwell pointing out that the agency’s website outlining technical compliance with HIPAA has not been updated since 2006, “years before an app store existed, much less the modern mobile device.”

As such, companies both large and small are struggling to determine if their mobile health apps are in compliance with HIPAA regulations. Some have hired legal teams just to determine, with some level of certainty, whether their product is in compliance.

“In order to make sure that mobile health apps and other companies can in good faith comply with these [important] protections, we ask that HHS provide clear, easily accessible and up to date regulatory guidance for HIPAA compliance with regard to new technologies,” according to the letter.

The congressmen also called for:

  • The development of Implementation standards by the Office of Civil Rights to help companies conform to regulation and avoid enforcement action
  • Clarity on HIPAA obligations for companies that store data in the cloud
  • The assignment of HHS employees with technical expertise to regularly engage with companies in the emergent healthcare technology space.

Read the full letter.

 

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.